Pss16 - Cost Per Responder Analysis of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Versus Non-Biologic Systemic Therapy in the Treatment of Moderate to Severe Plaque Psoriasis

Becla, L.; Carrascosa, J.M.; Antunes, Joana; Bewley, Anthony; Perälä, Miia; Charrua, M.F.; O’shaughnessy, S.; Treloggen, J.R.; Sawyer, Laura; Cornic, L.

doi:10.1016/j.jval.2018.09.2516

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential cost–benefit implications when using Cal/BD foam as a treatment for beyond-mild psoriasis are yet to be determined. It has been suggested that the use of Cal/BD foam as opposed to systemic treatment may result in cost savings [ 24 ]. Given that treatment cost can impact an HCP’s choice of treatment, further insights from real-world experience would help determine the most effective use of Cal/BD foam as a treatment option in this patient segment.…”

Section: Discussionmentioning

confidence: 99%

Real-World Experience Using Topical Therapy—Calcipotriol and Betamethasone Dipropionate Foam in Adults with Beyond-Mild Psoriasis

Aschoff

Martorell

Anger

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Determining optimal treatment for moderate plaque psoriasis can be challenging. Recent studies have demonstrated the effectiveness of calcipotriol and betamethasone dipropionate (Cal/BD) foam in patients with moderate-to-severe plaque psoriasis. Methods: This research explored the use of Cal/BD foam in patients with beyond-mild psoriasis (defined as patients eligible for topical treatment, systemic treatment, or combined topical/systemic treatments) using an online questionnaire, retrospective medical-record review, and by capturing the attitudes and treatment approaches of dermatology specialists. Results: Data from 409 patients with beyondmild psoriasis treated with Cal/BD foam were provided by 120 dermatology specialists from Germany, Spain, and the UK. Cal/BD foam was prescribed as monotherapy for most (58%) patients and was considered to be effective. Cal/BD foam was infrequently used in combination with biologics (7%) in this segment; 26% of patients received Cal/BD foam in combination with a non-biologic systemic treatment. Cal/BD foam prescribers generally use topical agents to bridge the waiting time to non-biologic/biologic systemic treatment, and as an add-on to systemic treatment for residual lesions. Conclusions: In patients with beyond-mild psoriasis, the most commonly prescribed topical medication was Cal/BD foam, which was regarded as an effective treatment. Further research is needed to determine optimal use of Cal/BD foam in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%